These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 34712233)

  • 21. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
    Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
    J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
    Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
    Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
    Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
    Front Immunol; 2022; 13():997589. PubMed ID: 36131934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
    Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
    J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.
    Frame DG; Geer M; Kasha S; Markstrom D; Scappaticci G; Feeney T; Hayduk A; Mansoor HM; Oberfeld A; D'Antonio H; Anand S; Choi SW; Maciejewski J; Pawarode A; Riwes MM; Tewari M; Magenau J; Ghosh M
    Front Immunol; 2024; 15():1403145. PubMed ID: 38947326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
    Li C; Zhou F; Wang J; Chang Q; Du M; Luo W; Zhang Y; Xu J; Tang L; Jiang H; Liu L; Kou H; Lu C; Liao D; Wu J; Wei Q; Ke S; Deng J; Liu C; Mei H; Hu Y
    J Hematol Oncol; 2023 Jan; 16(1):5. PubMed ID: 36681817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
    Costa BA; Flynn J; Nishimura N; Devlin SM; Farzana T; Rajeeve S; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Hultcrantz M; Korde N; Lesokhin AM; Shah UA; Tan CR; Giralt SA; Usmani SZ; Nath K; Mailankody S
    Blood Cancer J; 2024 May; 14(1):84. PubMed ID: 38802346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Filgrastim associations with CAR T-cell therapy.
    Gaut D; Tang K; Sim MS; Duong T; Young P; Sasine J
    Int J Cancer; 2021 Mar; 148(5):1192-1196. PubMed ID: 33091961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
    Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
    Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
    Brammer JE; Braunstein Z; Katapadi A; Porter K; Biersmith M; Guha A; Vasu S; Yildiz VO; Smith SA; Buck B; Haddad D; Gumina R; William BM; Penza S; Saad A; Denlinger N; Vallakati A; Baliga R; Benza R; Binkley P; Wei L; Mocarski M; Devine SM; Jaglowski S; Addison D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
    Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
    Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
    Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
    Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
    Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
    Front Immunol; 2022; 13():858021. PubMed ID: 35432352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.
    Elgohary G; Yang Y; Gergis M; Yi D; Gergis U
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e142-e151. PubMed ID: 38267353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    Nagle SJ; Murphree C; Raess PW; Schachter L; Chen A; Hayes-Lattin B; Nemecek E; Maziarz RT
    Am J Hematol; 2021 Apr; 96(4):455-461. PubMed ID: 33529419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia.
    Mao Y; Xu X
    Ann Clin Lab Sci; 2021 Nov; 51(6):790-794. PubMed ID: 34921032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.